The University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
Curr Opin Gastroenterol. 2021 Jul 1;37(4):357-363. doi: 10.1097/MOG.0000000000000740.
In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD).
Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn's disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies.
The IBD physicians' therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care.
在炎症性肠病快速发展的世界中，本综述讨论和总结了新药靶点和主要临床试验结果，以便为治疗炎症性肠病（IBD）患者的医生提供最新信息。
正在开发治疗 IBD 的多种新机制，其中许多在溃疡性结肠炎和克罗恩病患者中均显示出有前景的结果。除了疗效外，这些治疗方法中的一些可能比现有疗法具有更好的安全性。
IBD 医生的治疗手段正在迅速扩展，为了为患者提供最佳的个体化护理，需要了解这些新进展。
